Fig. 1. EμMYC- and v-Abl–driven tumor onset is unaffected by PLK4 transgene expression.

(A) Kaplan-Meier analysis of tumor-free survival of EμMYC and EμMYC/Plk4 transgenic mice kept on doxycycline (DOX)–containing food after weaning (day 28) until disease onset. EμMYC median survival 89 days (n = 15), EμMYC/Plk4 median survival 73 days (n = 18). Log-rank (Mantel-Cox) P = 0.8009 (χ² = 0.06362), Breslow-Gehan-Wilcoxon P = 0.65 (χ² = 0.1963). (B) Plk4 mRNA expression assessed in tumors, which developed in EμMYC (n = 8) or EμMYC/Plk4 mice (n = 5), normalized to Hprt. (C) Percentage of EμMYC and EμMYC/Plk4 tumor cells presenting with 2, 3, 4, or >4 centrioles (n = 3 per genotype). (D) Example microscopy pictures of CP110 foci, marking centrioles in EμMYC and EμMYC/Plk4 tumor cells (scale bar, 30 μm). (E) Kaplan-Meier analysis of tumor-free survival of v-Abl–infected R26rtTA (n = 13, median survival 67.5 days) and R26rtTA/Plk4 (n = 14) transgenic mice (median survival 52 days). Pups received doxycycline before weaning via breastfeeding from their mothers that were kept on doxycycline. Log-rank (Mantel-Cox) P = 0.6097 (χ² = 0.2607), Breslow-Gehan-Wilcoxon P = 0.5611 (χ² = 0.3378). (F) Plk4 mRNA expression in tumors that developed in R26rtTA (n = 5) and R26rtTA/Plk4 (n = 9) mice after infection with v-Abl, normalized to Actin. (G) Percentage of v-Abl–driven tumor cells presenting with 2, 3, 4, or >4 centrioles isolated from R26rtTA (n = 2) and R26rtTA/Plk4 (n = 3) mice. Plk4 expression between genotypes was compared using the unpaired t test. Centriole counts were analyzed by Sidak’s multiple comparisons test. Data are shown as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.005, ns = not significant.